Morgan Stanley’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.16M | Buy |
3,045,573
+25,988
| +0.9% | +$69.6K | ﹤0.01% | 3626 |
|
|
2025
Q1 | $4.26M | Sell |
3,019,585
-936,587
| -24% | -$1.32M | ﹤0.01% | 4061 |
|
|
2024
Q4 | $7.87M | Buy |
3,956,172
+915,378
| +30% | +$1.82M | ﹤0.01% | 3603 |
|
|
2024
Q3 | $9.58M | Buy |
3,040,794
+75,565
| +3% | +$238K | ﹤0.01% | 3461 |
|
|
2024
Q2 | $9.37M | Buy |
2,965,229
+244,834
| +9% | +$774K | ﹤0.01% | 3374 |
|
|
2024
Q1 | $12.2M | Buy |
2,720,395
+1,156,521
| +74% | +$5.19M | ﹤0.01% | 3177 |
|
|
2023
Q4 | $2.6M | Buy |
1,563,874
+899,847
| +136% | +$1.49M | ﹤0.01% | 4777 |
|
|
2023
Q3 | $596K | Buy |
664,027
+11,249
| +2% | +$10.1K | ﹤0.01% | 5087 |
|
|
2023
Q2 | $1.4M | Buy |
652,778
+214,829
| +49% | +$462K | ﹤0.01% | 4627 |
|
|
2023
Q1 | $854K | Buy |
437,949
+87,176
| +25% | +$170K | ﹤0.01% | 4944 |
|
|
2022
Q4 | $1.35M | Buy |
350,773
+67,761
| +24% | +$260K | ﹤0.01% | 4697 |
|
|
2022
Q3 | $1.37M | Buy |
283,012
+77,444
| +38% | +$374K | ﹤0.01% | 4677 |
|
|
2022
Q2 | $1.63M | Buy |
205,568
+119,703
| +139% | +$951K | ﹤0.01% | 4684 |
|
|
2022
Q1 | $1.26M | Buy |
85,865
+15,022
| +21% | +$221K | ﹤0.01% | 4840 |
|
|
2021
Q4 | $1.43M | Sell |
70,843
-14,014
| -17% | -$283K | ﹤0.01% | 4830 |
|
|
2021
Q3 | $2.3M | Sell |
84,857
-164,670
| -66% | -$4.47M | ﹤0.01% | 4455 |
|
|
2021
Q2 | $6.08M | Buy |
249,527
+45,300
| +22% | +$1.1M | ﹤0.01% | 3583 |
|
|
2021
Q1 | $4.99M | Buy |
204,227
+94,416
| +86% | +$2.3M | ﹤0.01% | 3406 |
|
|
2020
Q4 | $3.52M | Buy |
109,811
+99,320
| +947% | +$3.18M | ﹤0.01% | 3645 |
|
|
2020
Q3 | $346K | Sell |
10,491
-2,094
| -17% | -$69.1K | ﹤0.01% | 4824 |
|
|
2020
Q2 | $589K | Buy |
+12,585
| New | +$589K | ﹤0.01% | 4519 |
|